Skip to main content
SpringerLink
Log in

Alectinib may be cost effective for ALK-positive NSCLC

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Carlson JJ, et al. Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer. PharmacoEconomics : 27 Feb 2018. Available from: URL: http://doi.org/10.1007/s40273-018-0625-6

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alectinib may be cost effective for ALK-positive NSCLC. PharmacoEcon Outcomes News 798, 6 (2018). https://doi.org/10.1007/s40274-018-4753-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-4753-1

Search

Navigation